摘要
目的针对功能性便秘可能的发病因素实施干预,探讨抗抑郁药、促胃肠动力药及心理治疗对功能性便秘的治疗作用,研究功能性便秘发病的可能机制。方法选择2008年6月-2008年12月门诊功能性便秘患者78例,均符合罗马Ⅲ诊断标准,其中69例随访时间按规定要求完成。患者按干预方法分为以下4组:氟哌噻吨和美利曲辛复合制剂(商品名:黛力新)组19例,心理治疗组19例,莫沙必利(商品名:加斯清)组18例,莫沙必利+心理治疗+黛力新组13例,疗程均为2周,用药前及治疗结束后分别进行SCL-90精神评分及症状评分。结果各组FC患者接受药物干预及心理治疗后,精神和躯体症状明显改善。结论FC患者脑-肠之间存在密切的联系,支持脑-肠互动在FC发病机制中的重要作用。
Objective To evaluate the efficacy of functional constipation （ FC ） with antide- pressant, gastrokinetic agents and psychotherapy, and to investigate the pathological mechanism of FC. Methods From June 2008 to December 2008, 78 patients with functional constipation, who fulfilled the Rome III criteria were recruited. Among them 69 patients completed the trial. The patients were di- vided into Deanxit treatment group（ n = 19）, psychotherapy group（ n = 19）, Mosapride Citrate Tablets treatment group（ n = 18）, Deanxit ＋ Mosapride Citrate Tablets ＋ psychotherapy group（ n = 13）. The psychiatric symptoms and constipation symptoms were evaluated using Symptom Checklist -90 （SCL- 90） and constipation symptom table before and after 2 weeks treatment. Results The symptoms of FC and quality of life of all patients were improved after treatment. Conclusion There is a close relation between brain and gut in patients with FC, which may be involved in the pathogenesis of FC.
出处
《医药论坛杂志》
2010年第2期47-49,共3页
Journal of Medical Forum
关键词
功能性便秘
黛力新
心理治疗
促胃肠动力药
Functional constipation
Deanxit
Psychotherapy
Gastrokinetic agents
